DERM Dermira, Inc.

27.85
+0.33  (1%)
Previous Close 27.52
Open 27.44
Price To book 2.82
Market Cap 1.16B
Shares 41,521,000
Volume 348,837
Short Ratio 4.12
Av. Daily Volume 482,164

SEC filingsSee all SEC filings

  1. 8-K - Current report 17848659
  2. 8-K - Current report 17832356
  3. 8-K - Current report 17826510
  4. 8-K - Current report 17822399
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822195

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third and final trial met primary endpoint - January 19, 2017. FDA filing due 3Q 2017.
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
Olumacostat glasaretil (DRM01)
Acne
Phase 3 data released June 2016. NDA Filing 2H 2017.
Glycopyrronium tosylate (DRM04)
Primary axillary hyperhidrosis

Latest News

  1. Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
  2. Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
  3. Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
  4. Here's Why Dermira Fell as Much as 18.7% This Morning
  5. Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
  6. Dermira reports 1Q loss
  7. Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
  8. Dermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017
  9. Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017
  10. Dermira to Present at Needham 16th Annual Healthcare Conference
  11. Xenon Pharma Dumps Acne Drug After Study Failure
  12. Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)
  13. Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
  14. Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
  15. Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  16. New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
  17. Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
  18. Dermira to Present at Cowen and Company 37th Annual Health Care Conference
  19. Dermira, Inc. :DERM-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
  20. Dermira Prices $168.5 Million Public Offering of Common Stock